Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2019
Reporting Period: Single event date (June 11, 2019)
Business Context: The Company is an emerging growth company focused on developing novel therapies for cancer and neurodegenerative diseases, such as Alzheimer's.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a media interview and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely discloses a media event.
Guidance, Outlook, and Management Commentary
- Management Commentary: CEO Dr. Raymond Tesi and CFO David Moss were interviewed by NetworkNewsAudio regarding the Company's novel approach to treating unsolved problems in cancer therapy and neurodegenerative diseases.
- Guidance/Outlook: No specific financial guidance or operational outlook was provided in this filing.
- Risks/Contingencies: No new risks or contingencies were disclosed in this specific report.
Important Facts for Investor Verification
- Verify the content of the press release furnished as Exhibit 99.1 to understand the specific details of the Company's therapeutic approach discussed in the interview.
- Note that the press release and interview are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings.
- Confirm the Company's status as an emerging growth company, which may affect financial reporting requirements.